Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
82.54
-0.76 (-0.91%)
At close: Jul 31, 2026, 4:00 PM EDT
82.57
+0.03 (0.04%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 423 employees as of December 31, 2025. The number of employees increased by 73 or 20.86% compared to the previous year.
Employees
423
Change (1Y)
73
Growth (1Y)
20.86%
Revenue / Employee
$3,566,095
Profits / Employee
$824,688
Market Cap
9.79B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 423 | 73 | 20.86% |
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,402 |
| Corcept Therapeutics | 730 |
| Cytokinetics | 673 |
| Crinetics Pharmaceuticals | 594 |
| Krystal Biotech | 295 |
| Summit Therapeutics | 265 |
| Apogee Therapeutics | 261 |
HALO News
- 8 days ago - Halozyme to Report Second Quarter 2026 Financial and Operating Results - PRNewsWire
- 9 days ago - Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs - FXEmpire
- 11 days ago - Halozyme announces global collaboration, license agreement with Incyte - TheFly
- 11 days ago - Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - PRNewsWire
- 4 weeks ago - Halozyme Appoints David Ramsay as President Drug Delivery - PRNewsWire
- 5 weeks ago - LifeMD partners with Halozyme subsidiary for exclusive testosterone program - TheFly
- 6 weeks ago - 20 growth stocks priced as value stocks - Market Watch
- 6 weeks ago - Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 - PRNewsWire